Product Information
TRILEPTAL 300 MG/5 ML SUSP is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $1.9303 per ML under NDC 00078035752. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on May 25, 2001. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the oxcarbazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
60 mg/mL
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078035752
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
OXCARBAZEPINEApproval Type
New Drug (NDA)
FDA Application
NDA021285FDA Approved
5/25/2001
TE Code
AB
On Market Since
5/30/2001
Pharmacological Classes
Price Statistics
The NADAC for TRILEPTAL 300 MG/5 ML SUSP has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 124.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9303 per ML |
|---|---|
| All-time high | $1.9345 (May 13, 2026) |
| All-time low | $0.8587 (Nov 28, 2013) |
| 52-week high | $1.9345 |
| 52-week low | $1.8752 |
| Median price | $1.5409 |
| Average price | $1.5098 |
| Largest weekly change | +14.9% (Jan 14, 2015) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the oxcarbazepine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRILEPTAL 300 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for TRILEPTAL 300 MG/5 ML SUSP, manufactured by Novartis Pharmaceuticals Corporation, is $1.9303 per ML (NDC 00078035752), effective Aug 19, 2026.
How has the price of TRILEPTAL 300 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for TRILEPTAL 300 MG/5 ML SUSP has risen 124.8%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRILEPTAL 300 MG/5 ML SUSP?
Since Nov 28, 2013, the NADAC for TRILEPTAL 300 MG/5 ML SUSP has ranged from a low of $0.8587 (Nov 28, 2013) to a high of $1.9345 (May 13, 2026), with a median of $1.5409 per ML.
Are there cheaper alternatives to TRILEPTAL 300 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of TRILEPTAL 300 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRILEPTAL 300 MG/5 ML SUSP?
TRILEPTAL 300 MG/5 ML SUSP (NDC 00078035752) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.